（Singapore，03.03.2025）In a significant advancement for diabetes care, BUZUD, in collaboration with Tan Tock Seng Hospital (TTSH), has launched an innovative AI-powered mobile application alongside a wearable Continuous Glucose Monitoring (CGM) device. Named CARB-CGM, the new solution was introduced during a launch event on 26 February, aiming to transform diabetes management and enable patients to manage their health more effectively.
As diabetes is projected to affect up to 1 million individuals in Singapore by 2050, this collaborative effort responds to the urgent need for innovative healthcare solutions. The CARB-CGM system integrates cutting-edge AI technology with real-time glucose monitoring, streamlining the complex process of diabetes management. It allows for precise insulin dosage decisions, thereby reducing risks associated with hyperglycaemia and hypoglycaemia.
The key feature of the CARB-CGM system is its real-time glucose monitoring capability, provided by the BUZUD CGM device through a wearable sensor. This enables continuous tracking of glucose levels. Additionally, the system includes an AI-powered dietary analysis tool that allows patients to photograph their meals. The app then identifies the food and estimates its carbohydrate content for more accurate insulin dosing. Another significant feature developed in collaboration with TTSH is the calculation of the Insulin Sensitivity Factor, ensuring personalized insulin dosage recommendations based on individual health data.
Adjunct Associate Professor Daniel Chew, Division Chairman (Medicine) at TTSH, emphasized the daily decision-making challenges faced by diabetes patients and the importance of empowering them and their caregivers. “An enhanced CARB-CGM solution can eliminate much of the guesswork involved in insulin administration, reducing anxiety and unnecessary hospital visits by providing the right tools for managing health safely at home and at work,” he said.
Frankie Fan, CEO of BUZUD, noted that the collaboration marks a pivotal moment in patient care, delivering better glycaemic control and personalized support. “We’re reimagining diabetes management through AI technology, focusing on reducing complications and enhancing the quality of life. This aligns with our mission to leverage technology for superior healthcare outcomes,” Fan explained.
The collaboration between TTSH and BUZUD, facilitated by the National Healthcare Group’s (NHG) Centre for Medical Technologies and Innovations (CMTi), underscores the critical role of public-private partnerships in meeting healthcare needs. Adjunct Associate Professor Chew added that this partnership leverages TTSH’s innovative culture and demonstrates the transformative potential of AI technologies in enhancing patient care and empowerment.
The partnership was formalized with the signing of a Research Collaboration Agreement (RCA) between Mr. Christopher Soh, Deputy Director of Nursing at TTSH, and Mr. Frankie Fan, CEO of BUZUD. Following this launch, the next steps include a validation study to assess the accuracy and effectiveness of the CARB-CGM system, with potential refinements to further enhance its capabilities. This will be followed by a pilot adoption phase with a select group of patients, before expanding to more patients in subsequent stages.
